Market Cap 972.91M
Revenue (ttm) 796.85M
Net Income (ttm) 30.44M
EPS (ttm) N/A
PE Ratio 18.25
Forward PE 19.15
Profit Margin 3.82%
Debt to Equity Ratio 0.78
Volume 1,151,000
Avg Vol 1,894,528
Day's Range N/A - N/A
Shares Out 342.57M
Stochastic %K 58%
Beta 1.54
Analysts Sell
Price Target $3.10

Company Profile

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealt...

Industry: Health Information Services
Sector: Healthcare
Phone: 855 268 2822
Address:
2701 Olympic Boulevard, Santa Monica, United States
Yayomamon
Yayomamon May. 13 at 10:42 PM
$GDRX fuck you wendy useless ass ceo
0 · Reply
bigd1
bigd1 May. 13 at 9:28 PM
$GDRX ”Limited Downside” means buy
0 · Reply
bigd1
bigd1 May. 13 at 9:27 PM
$GDRX booyah
0 · Reply
fishinNbanjo
fishinNbanjo May. 13 at 7:33 PM
$GDRX hot garbage
0 · Reply
mph1
mph1 May. 13 at 6:53 PM
$GDRX $HIMS is building a real consumer healthcare platform. $GDRX still looks like a prescription coupon middleman trying to reinvent itself. Hims owns: * the patient relationship * telehealth * prescribing * subscriptions * fulfillment * recurring engagement That’s a much stronger long-term model than relying on pharmacy transaction fees. Meanwhile: * $HIMS continues putting up major growth * $GDRX user growth and subscriptions have been shrinking * GoodRx revenue has largely stalled Consumers want frictionless healthcare, not more coupon searching. $HIMS feels like the future. $GDRX feels like a utility layer that can get commoditized. This is why people are short GDRX.
1 · Reply
bigd1
bigd1 May. 13 at 6:43 PM
$HIMS peptides mean nothing and $GDRX had 1/3 or 33% of ALL GLP-1 volume on their platform and incrementally more on TrumpRx
2 · Reply
Mr_Sparkles
Mr_Sparkles May. 13 at 6:40 PM
$GDRX crickets again from the most exciting management team 👍 good work
0 · Reply
bigd1
bigd1 May. 13 at 6:02 PM
$HIMS this is going to $0 its compounded business is dead cuz of Novo and now theyre just offering what $GDRX offers but worse
0 · Reply
bigd1
bigd1 May. 13 at 6:00 PM
$GDRX these guys all think its a free lunch out here
0 · Reply
bigd1
bigd1 May. 13 at 5:52 PM
$GDRX $HIMS its because BofA underwrote IPO on a loser and cant admit defeat
0 · Reply
Latest News on GDRX
GoodRx price target raised to $4 from $3 at TD Cowen

2026-05-11T14:25:10.000Z - 2 days ago

GoodRx price target raised to $4 from $3 at TD Cowen


Big Pharma Runs Its Checkout Counter Through GoodRx

May 7, 2026, 1:08 PM EDT - 6 days ago

Big Pharma Runs Its Checkout Counter Through GoodRx


GoodRx Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 6 days ago

GoodRx Holdings Earnings Call Transcript: Q1 2026


GoodRx Reports First Quarter 2026 Results

May 6, 2026, 4:05 PM EDT - 7 days ago

GoodRx Reports First Quarter 2026 Results


GoodRx offers Ozempic pill for Type 2 diabetes

2026-05-01T13:29:43.000Z - 12 days ago

GoodRx offers Ozempic pill for Type 2 diabetes

NVO


GoodRx price target lowered to $3.50 from $7 at Wells Fargo

2026-03-04T11:47:25.000Z - 2 months ago

GoodRx price target lowered to $3.50 from $7 at Wells Fargo


GoodRx price target lowered to $3.50 from $7 at Wells Fargo

2026-03-03T18:55:37.000Z - 2 months ago

GoodRx price target lowered to $3.50 from $7 at Wells Fargo


GoodRx price target lowered to $3.50 from $4.50 at Citi

2026-03-03T11:26:49.000Z - 2 months ago

GoodRx price target lowered to $3.50 from $4.50 at Citi


GoodRx price target lowered to $2.50 from $4 at Goldman Sachs

2026-03-02T11:36:09.000Z - 2 months ago

GoodRx price target lowered to $2.50 from $4 at Goldman Sachs


GoodRx price target lowered to $3 from $6 at Deutsche Bank

2026-02-27T14:42:12.000Z - 2 months ago

GoodRx price target lowered to $3 from $6 at Deutsche Bank


GoodRx price target lowered to $3 from $6 at TD Cowen

2026-02-27T13:52:20.000Z - 2 months ago

GoodRx price target lowered to $3 from $6 at TD Cowen


GoodRx price target lowered to $2 from $4 at UBS

2026-02-27T13:38:01.000Z - 2 months ago

GoodRx price target lowered to $2 from $4 at UBS


GoodRx price target lowered to $2 from $4 at UBS

2026-02-27T13:29:24.000Z - 2 months ago

GoodRx price target lowered to $2 from $4 at UBS


GoodRx price target lowered to $3 from $4 at Mizuho

2026-02-27T12:49:10.000Z - 2 months ago

GoodRx price target lowered to $3 from $4 at Mizuho


GoodRx Holdings Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 2 months ago

GoodRx Holdings Earnings Call Transcript: Q4 2025


GoodRx Reports Fourth Quarter and Full Year 2025 Results

Feb 25, 2026, 4:05 PM EST - 2 months ago

GoodRx Reports Fourth Quarter and Full Year 2025 Results


GoodRx Powers Pricing for Leading Brand Medications on TrumpRx

Feb 5, 2026, 7:44 PM EST - 3 months ago

GoodRx Powers Pricing for Leading Brand Medications on TrumpRx


GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies

Jan 8, 2026, 9:00 AM EST - 4 months ago

GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies


GoodRx Holdings Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 6 months ago

GoodRx Holdings Earnings Call Transcript: Q3 2025


GoodRx Reports Third Quarter 2025 Results

Nov 4, 2025, 4:05 PM EST - 6 months ago

GoodRx Reports Third Quarter 2025 Results


Should You Buy GoodRx Stock?

Nov 4, 2025, 9:55 AM EST - 6 months ago

Should You Buy GoodRx Stock?


GoodRx Teams With Kroger on Prescription Savings

Oct 1, 2025, 5:17 PM EDT - 8 months ago

GoodRx Teams With Kroger on Prescription Savings

KR


Is Novo Nordisk deal the much-needed catalyst for Goodrx stock?

Aug 18, 2025, 3:47 PM EDT - 9 months ago

Is Novo Nordisk deal the much-needed catalyst for Goodrx stock?

NVO


Novo Cuts Price of Ozempic in Half for Cash Buyers

Aug 18, 2025, 10:29 AM EDT - 9 months ago

Novo Cuts Price of Ozempic in Half for Cash Buyers

NVO


GoodRx Holdings Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 9 months ago

GoodRx Holdings Earnings Call Transcript: Q2 2025


GoodRx Reports Second Quarter 2025 Results

Aug 6, 2025, 4:05 PM EDT - 10 months ago

GoodRx Reports Second Quarter 2025 Results


GoodRx Holdings Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

GoodRx Holdings Earnings Call Transcript: Q1 2025


GoodRx Reports First Quarter 2025 Results

May 7, 2025, 4:13 PM EDT - 1 year ago

GoodRx Reports First Quarter 2025 Results


GoodRx Launches eCommerce Offering for Retail Pharmacies

Apr 3, 2025, 2:02 PM EDT - 1 year ago

GoodRx Launches eCommerce Offering for Retail Pharmacies


GoodRx Holdings Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

GoodRx Holdings Earnings Call Transcript: Q4 2024


GoodRx Reports Fourth Quarter and Full Year 2024 Results

Feb 27, 2025, 6:05 AM EST - 1 year ago

GoodRx Reports Fourth Quarter and Full Year 2024 Results


Yayomamon
Yayomamon May. 13 at 10:42 PM
$GDRX fuck you wendy useless ass ceo
0 · Reply
bigd1
bigd1 May. 13 at 9:28 PM
$GDRX ”Limited Downside” means buy
0 · Reply
bigd1
bigd1 May. 13 at 9:27 PM
$GDRX booyah
0 · Reply
fishinNbanjo
fishinNbanjo May. 13 at 7:33 PM
$GDRX hot garbage
0 · Reply
mph1
mph1 May. 13 at 6:53 PM
$GDRX $HIMS is building a real consumer healthcare platform. $GDRX still looks like a prescription coupon middleman trying to reinvent itself. Hims owns: * the patient relationship * telehealth * prescribing * subscriptions * fulfillment * recurring engagement That’s a much stronger long-term model than relying on pharmacy transaction fees. Meanwhile: * $HIMS continues putting up major growth * $GDRX user growth and subscriptions have been shrinking * GoodRx revenue has largely stalled Consumers want frictionless healthcare, not more coupon searching. $HIMS feels like the future. $GDRX feels like a utility layer that can get commoditized. This is why people are short GDRX.
1 · Reply
bigd1
bigd1 May. 13 at 6:43 PM
$HIMS peptides mean nothing and $GDRX had 1/3 or 33% of ALL GLP-1 volume on their platform and incrementally more on TrumpRx
2 · Reply
Mr_Sparkles
Mr_Sparkles May. 13 at 6:40 PM
$GDRX crickets again from the most exciting management team 👍 good work
0 · Reply
bigd1
bigd1 May. 13 at 6:02 PM
$HIMS this is going to $0 its compounded business is dead cuz of Novo and now theyre just offering what $GDRX offers but worse
0 · Reply
bigd1
bigd1 May. 13 at 6:00 PM
$GDRX these guys all think its a free lunch out here
0 · Reply
bigd1
bigd1 May. 13 at 5:52 PM
$GDRX $HIMS its because BofA underwrote IPO on a loser and cant admit defeat
0 · Reply
bigd1
bigd1 May. 13 at 5:50 PM
$GDRX its also why $HIMS keeps getting favorable coverage while putting up dogshit results
0 · Reply
bigd1
bigd1 May. 13 at 5:49 PM
$GDRX same with Barclays - ok this makes sense. BofA and Barclays are gonna lose a shitload an they know it but neither wants to cover and trigger a short sale, theyre waiting for the other to do it
0 · Reply
bigd1
bigd1 May. 13 at 5:48 PM
$GDRX HA thats why Allen Lutz wont put a buy on $GDRX, hes long $HIMS. BofA is short GDRX and WAAAAY WRONG
0 · Reply
bigd1
bigd1 May. 13 at 4:35 PM
$GDRX fuck it im doin it - try to connect with Wendy on linkedin and ask her to unload the rest of her buyback authority left in one massive trade blow up shorts
0 · Reply
bigd1
bigd1 May. 13 at 4:08 PM
$GDRX look at the revenue growth rate on the pharma direct line item vs the decline rate of legacy biz - roll those out into perpetuity and what do you get for total rev?
0 · Reply
Yayomamon
Yayomamon May. 13 at 3:00 PM
$GDRX honestly only thing to do now is hold and pray Wendy fucked is she belongs in prison hopefully company doesn’t go bankrupt we’re down 90% over the last 5 years crazy to think no one made money here during that time
0 · Reply
Yayomamon
Yayomamon May. 13 at 2:26 PM
$GDRX might be screwed here we have no volume no good news lately Wendy failed the stock holders fuck that bitch
1 · Reply
bigd1
bigd1 May. 13 at 1:41 PM
$GDRX https://stocks.apple.com/ANGzQ9fH1RAyYf3g-gExlHA
1 · Reply
bigd1
bigd1 May. 13 at 12:20 PM
$GDRX https://stockstory.org/us/stocks/nasdaq/gdrx/news/earnings-call/the-5-most-interesting-analyst-questions-from-goodrxs-q1-earnings-call
0 · Reply
bigd1
bigd1 May. 12 at 11:44 PM
$O set the nuke off on $GDRX on Jim Cramer got a slot for next week I’ve got you guys covered
0 · Reply
bigd1
bigd1 May. 12 at 11:36 PM
$GDRX the extreme losses are over its upside from here on out shut up AI stonk news
1 · Reply
topstockalerts
topstockalerts May. 12 at 11:33 PM
Jim Cramer’s “Mad Money” lightning round leaned cautiously bullish on select industrial and energy names, while being more disciplined on recent big winners. On Chevron, he was firmly positive, telling a caller they are “absolutely right” to consider buying it. He highlighted the company’s strong fundamentals, especially its robust free cash flow and a dividend yield of about 3.8%. He also pointed out that even though oil prices are at similar levels to past periods when Chevron traded higher, the stock still offers value thanks to its balance sheet strength and shareholder returns. His bottom line was clear: “pull the trigger,” reinforcing a buy stance. With GoodRx, his tone was much more cautious. He described it as a speculative investment with “limited downside,” but emphasized the inherent risk, essentially warning that investors should only approach it if they are comfortable with the possibility of extreme losses. $CVX $GDRX $VRT $STRL
0 · Reply